HEcoPerMed stands for “Healthcare- and pharma-economics in support of the International Consortium for Personalised Medicine – ICPerMed". The project responds to the demand for economic models that evaluate treatments made possible through innovations in personalised medicine. HEcoPerMed also seeks to identify funding and reimbursement mechanisms that provide financial incentives for the rapid development and uptake of such innovations. HEcoPerMed goes beyond current assessment and payment models in order to serve the need of personalised medicine for more comprehensive cost-effectiveness estimates – incorporating patient and societal perspectives – and for sustainable affordability of cutting-edge health innovations.

Read more

What is the aim of HEcoPerMed?

Our project aims to identify the best modelling and payment strategies for personalised medicine to differentiate between promises and reality.

Guidance on health economic modelling

Personalised medicine aims to optimally match patient and treatment by assessing the characteristics of patients related to treatment effectiveness.

Application of best practice health economic modelling in personalised medicine

Develop cost-effectiveness and budget impact models for three case studies by using publicly available input data.

Financing and payment models

Identify funding and reimbursement mechanisms that provide financial incentives for the rapid development and uptake of such innovations.

Benefits and challenges for European health care

Assess the role and relevance of personalised medicine for the future of the European Social Models of Health Care.

Dissemination and communication

Disseminate the obtained results and organise two scientific workshops and a stakeholder conference.

Project partners

The project consortium consists of six partners from five European countries.